This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BIO CEO Conference Live Blog

NEW YORK ( TheStreet) -- The 2012 BIO CEO & Investor Conference kicks off this morning here at the Waldorf-Astoria Hotel.

The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks.

Biotech companies scheduled to present today include Celsion Pharmaceuticals (CLSN), Cyclacel Pharmaceuticals (CYCC - Get Report), Chelsea Therapeutics (CHTP), Navidea Biopharmaceuticals (NAVB), Galena Biopharma (GALE), Titan Pharmaceuticals (TTNP) and Oxigene (OXGN).

Today's agenda also includes panel discussions on cancer clinical trials, the "beta amyloid debate" in Alzheimer's disease drug research and biotech financing.

On Tuesday, biotech and drug presenters include Delcath Systems (DCTH), Keryx Pharmaceuticals (KERX - Get Report), Oncothyreon (ONTY), Acorda Therapeutics (ACOR - Get Report) and Idenix Pharmaceuticals (IDIX). Gilead Sciences' (GILD - Get Report) President John Milligan will also be featured in a "fireside chat."

To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag.

--Written by Adam Feuerstein in New York.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CHTP $0.00 0.00%
IDIX $24.50 0.20%
ACOR $34.49 0.00%
CYCC $1.01 0.00%
GILD $101.38 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs